Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jonathan Craighead

Orthopaedic Surgery Jefferson City, MO Medical Doctor

NPI 1346226289 CMS profile 151133

1225 West Stadium Blvd, Jefferson City, MO 65109

Open in the dashboard

General payments

$11,363

130 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jonathan Craighead of Jefferson City, MO is reported in the CMS Open Payments database as having received $11,363 across 130 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 72nd percentile of Orthopaedic Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,072 27
2024 General $120 5
2023 General $379 11
2022 General $3,341 24
2021 General $3,771 24
2020 General $204 11
2019 General $476 28

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jonathan Craighead
  • Orthopaedic Surgery median
  • Middle half of Orthopaedic Surgery
  • National median

In program year 2025, general payments to Jonathan Craighead were reported at $3,072. Among 15,343 Orthopaedic Surgery profiles paid that year, the median was $563 and the middle half received between $147 and $2,717.

Show as a table
Year Jonathan Craighead Orthopaedic Surgery median Middle half National median
2019 $476 $644 $140–$2,844 $163
2020 $204 $312 $75–$1,860 $114
2021 $3,771 $520 $117–$2,495 $132
2022 $3,341 $598 $128–$2,731 $149
2023 $379 $461 $128–$2,264 $160
2024 $120 $497 $134–$2,475 $164
2025 $3,072 $563 $147–$2,717 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Elite Orthopedics, LLC $6,448 28 payments
  2. Arthrex, Inc. $2,447 10 payments
  3. DePuy Synthes Sales Inc. $670 16 payments
  4. Zimmer Biomet Holdings, Inc. $307 8 payments
  5. Heraeus Medical, LLC. $208 6 payments
  6. Flexion Therapeutics, Inc. $141 9 payments
  7. Kowa Pharmaceuticals America, Inc. $125 6 payments
  8. Phathom Pharmaceuticals, Inc. $104 2 payments
  9. Vertex Pharmaceuticals Incorporated $96 4 payments
  10. Pfizer Inc. $83 6 payments
  11. Other $734 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Education $4,969 5 payments
  2. Travel and Lodging $3,378 10 payments
  3. Food and Beverage $3,015 115 payments
Products named General payments · program years 2019–2025
  1. PALACOS $208 6 payments
  2. Persona $204 3 payments
  3. Avenir $184 2 payments
  4. MONOVISC $157 9 payments
  5. Zilretta $141 9 payments
  6. VOQUEZNA $104 2 payments
  7. JOURNAVX $96 4 payments
  8. Seglentis $88 4 payments
  9. BIOBRACE 23MM $64 1 payment
  10. ELIQUIS $63 5 payments
  11. Other $1,036 55 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 19 drugs

Part D claims

3,663

Median for Orthopedic Surgery: 203

Drug cost

$21,374

Median for Orthopedic Surgery: $1,433

Branded share of claims

3.7%

Median for Orthopedic Surgery: 11.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Celecoxib Generic 376 $5,755
Meloxicam Generic 1,333 $4,292
Oxycodone Hcl Generic 322 $1,457
Tramadol Hcl Generic 455 $1,405
Methocarbamol Generic 87 $1,336
Diclofenac Sodium Generic 99 $1,336
Ondansetron Hcl Generic 296 $1,175
Erythromycin Erythromycin Base Brand 18 $1,018
Pregabalin Generic 42 $773
Dexamethasone Generic 245 $615

The 10 drugs with the highest cost, of 19 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 18,934 Part D prescribers listed as Orthopedic Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 77 billing codes

Paid by Medicare

$304,722

Of which drugs: $41,641

Medicare patients

670

Average age 75

Services billed

10,768

416 women, 254 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Diabetes 27%
Ischemic heart disease 22%
COPD 20%
Depression 18%
Atrial fibrillation 16%
Osteoporosis 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg J7325 Office 28 2,400 $16,735
Hyaluronan or derivative, synojoynt, for intra-articular injection, 1 mg J7331 Office 14 1,220 $10,180
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 284 3,522 $2,484

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
XYOSTED
  • Antares Pharma, Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

130 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Orthopaedic Surgery in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record